News Sentiment

TELA sentiment intelligence

Tela Bio Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 48 Balanced news tone 31 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Medical Devices Read-through group
Latest close 0.85 Week of 10 Jul 2026
Weighted tone 48/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings

80/100 classification confidence.

Company focus 20

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+17.4% over one week, -1.5% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

TELA - TELA Bio Inc Dividends

Market Reaction

Price moving ahead of tone

60/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings 80/100 classification
One-week reaction 17.4% Price confirming higher
Trend fit Trend inactive -1.5% over four weeks
Fair value -74.8% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 1
Neutral 26
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 20
Industry context 11
Sector context 0

Sources

Coverage mix

Publishers
Market source 10
Stock Titan 5
TradingView 4
Finviz 2
TradingKey 2
GuruFocus.com 2
StockStory 2
DonanımHaber 1

Event Lens

What the news is about

Classified themes
Earnings 19
Market update 9
Analyst action 1
Guidance 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 31
Finviz Direct company coverage

TELA - TELA Bio Inc Dividends

This page provides a detailed financial overview of TELA Bio Inc (TELA), including its stock performance, market capitalization, income, sales, and various financial ratios. It also lists key statistics like insider ownership, institutional ownership, analyst recommendations, and

Tone
Neutral 50/100
Event
Analyst action
Published
03 Jul 2026 01:10
Source
Finviz
Finviz Direct company coverage

TELA - TELA Bio Inc Options

This article provides a detailed financial overview of TELA Bio Inc (TELA) as of June 29, 2026. It includes key financial metrics such as market capitalization, income, sales, EPS, various ratios, and stock performance data. The company's short interest, insider/institutional own

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 18:11
Source
Finviz
TradingView Direct company coverage

TELA Bio, Inc. Actuals & Estimates (NASDAQ:TELA)

This article provides an overview of TELA Bio, Inc. (NASDAQ: TELA) stock performance, financial actuals, and analyst estimates. It details the company's current stock price, market capitalization, volatility, and future outlook based on analyst forecasts, alongside historical hig

Tone
Negative 40/100
Event
Guidance
Published
26 Jun 2026 06:39
Source
TradingView
TradingView Direct company coverage

Price to sales forward of TELA Bio, Inc. – NASDAQ:TELA

This article provides a brief overview of TELA Bio, Inc. (NASDAQ:TELA) specifically focusing on its forward price-to-sales ratio. It's presented within the context of TradingView's financial data offerings, indicating the company's financial metrics are available for analysis on

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 04:40
Source
TradingView
TradingView Direct company coverage

Price to book forward of TELA Bio, Inc. – NASDAQ:TELA

This article focuses on the "Price to book forward" metric for TELA Bio, Inc. (NASDAQ: TELA). It appears to be a financial data presentation rather than an analytical piece, originating from a platform like TradingView which provides market data and financial tools.

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 17:39
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of TELA Bio, Inc. – NASDAQ:TELA

This article focuses on the forward price-to-earnings ratio of TELA Bio, Inc. (NASDAQ: TELA). It appears to be a financial data page from TradingView, displaying basic financial metrics for the company. The page also provides navigational options for further financial analysis, n

Tone
Neutral 50/100
Event
Earnings
Published
24 Jun 2026 21:41
Source
TradingView
TradingKey Direct company coverage

TELA Bio Inc (TELA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for TELA Bio Inc (TELA), detailing its business segments. As of the latest update (April 6), the company's revenue streams are primarily OviTex, OviTex PRS, and "Other," with OviTex contributing the largest proportion. The data presented

Tone
Neutral 50/100
Event
Earnings
Published
19 Jun 2026 13:40
Source
TradingKey
TradingKey Direct company coverage

TELA Bio Inc (TELA) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of TELA Bio Inc (TELA), focusing on its support and resistance levels, various technical indicators, and moving averages. It highlights the stock's current price momentum score and suggests a "Sell" signal based on certain indicators. Th

Tone
Negative 38/100
Event
Market update
Published
17 Jun 2026 22:09
Source
TradingKey
Stock Titan Direct company coverage

TELA Bio (NASDAQ: TELA) director Thomas Paul files initial Form 3 ownership

TELA Bio, Inc. director Thomas Paul has filed an initial Form 3, which is a mandatory statement of beneficial ownership for company insiders. This filing identifies him as a director but does not report any specific stock transactions, derivative positions, or shareholdings withi

Tone
Neutral 50/100
Event
Market update
Published
11 Jun 2026 22:40
Source
Stock Titan
Stock Titan Direct company coverage

TELA Bio (NASDAQ: TELA) director Guido Neels granted stock and long-term options

TELA Bio director Guido Neels was granted stock awards totaling 23,600 and 11,925 shares, respectively, at a $0.00 strike price, along with two stock option grants for 17,335 and 17,550 shares at an exercise price of $0.935, expiring on June 9, 2036. These awards are routine comp

Tone
Neutral 50/100
Event
Market update
Published
11 Jun 2026 22:13
Source
Stock Titan
Stock Titan Direct company coverage

TELA Bio (NASDAQ: TELA) grants director new stock and options

TELA Bio director Joseph H. Capper has received new equity awards, including restricted stock units (RSUs) and stock options, as compensation. The grants consist of 11,675 and 11,925 RSUs, and options for 17,335 and 17,550 shares with an exercise price of $0.935 per share, expiri

Tone
Neutral 50/100
Event
Market update
Published
11 Jun 2026 22:11
Source
Stock Titan
GuruFocus Direct company coverage

TELA Bio Inc Annual Shareholders Meeting Transcript

TELA Bio Inc held its 2026 Annual Shareholders Meeting in an all-virtual format, presided over by Director and Chairman of the Board, Doug Evans. The meeting aimed to maximize stockholder participation through increased accessibility. The transcript records the official calling t

Tone
Neutral 50/100
Event
Market update
Published
09 Jun 2026 13:40
Source
GuruFocus
Stock Titan Direct company coverage

TELA Bio (NASDAQ: TELA) holder reports 2.44M shares, 5.5% stake

Laurence W. Lytton has filed an amended Schedule 13G/A, reporting a beneficial ownership of 2,442,341 shares of TELA Bio, Inc. (NASDAQ: TELA) Common Stock, which constitutes a 5.5% stake in the company. This percentage is based on 44,740,371 shares outstanding as of March 16, 202

Tone
Neutral 50/100
Event
Deals and strategy
Published
15 May 2026 17:08
Source
Stock Titan
Simply Wall Street Direct company coverage

Analysts Have Been Trimming Their TELA Bio, Inc. (NASDAQ:TELA) Price Target After Its Latest Report

TELA Bio, Inc. (NASDAQ:TELA) shares dropped 10% after its first-quarter results, despite revenues meeting expectations. Analysts subsequently lowered their average price target by 35% to US$2.25, indicating increased pessimism about the company's intrinsic value, even though loss

Tone
Negative 36/100
Event
Earnings
Published
15 May 2026 12:08
Source
Simply Wall Street
Stock Titan Direct company coverage

TELA Bio (NASDAQ: TELA) Q1 2026 revenue edges up as net loss widens

TELA Bio reported a slight increase in Q1 2026 revenue to $19.1 million, a 3% rise year-over-year, primarily driven by higher OviTex unit sales and international demand. Despite this, the company's net loss widened to $12.3 million due to increased interest expenses from a new cr

Tone
Neutral 50/100
Event
Earnings
Published
13 May 2026 19:40
Source
Stock Titan